Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy.
about
Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis.Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009.Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML).Pediatric chronic myeloid leukemia is a unique disease that requires a different approachEuropean LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalitiesSignificance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitorsYounger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV.Ethical and clinical aspects of intensive care unit admission in patients with hematological malignancies: guidelines of the ethics commission of the French society of hematology.Social Media and the Adolescent and Young Adult (AYA) Patient with Cancer.Prognostic discrimination based on the EUTOS long term survival score within the international registry for chronic myeloid leukemia in children and adolescents.Can prognostic scoring systems for chronic myeloid leukemia as established in adults be applied to pediatric patients?Unfavorable outcome of chronic myelogenous leukemia in adolescent and young adults treated with tyrosine kinase inhibitors.Response dynamics of pediatric patients with chronic myeloid leukemia on imatinib therapy.E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy.Treatment of chronic phase chronic myeloid leukemia with imatinib.Severe dyspnoea in a patient with chronic myelogenous leukaemia on a tyrosine kinase inhibitor.Comparative Study of Clinico-hematological Features, Molecular Spectrum and Response to Imatinib in Chronic Myelogenous Leukemia Patients: Pediatric and Adolescent Versus Adults.Transplants of unrelated cord blood or sibling allogeneic peripheral blood stem cells/bone marrow in adolescent and young adults with chronic myeloid leukemia: comparable outcomes but better chronic GVHD-free and relapse-free survival among survivorDiagnostic and prognostic cytogenetics of chronic myeloid leukaemia: an update.Differences among young adults, adults and elderly chronic myeloid leukemia patients.Increased megakaryocytic proliferation, pro-platelet deposition and expression of fibrosis-associated factors in children with chronic myeloid leukaemia with bone marrow fibrosis.Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial.Optimal management for pediatric chronic myeloid leukemia.The first concurrent diagnosis of acute symptomatic Babesiosis and chronic myeloid leukemia in a healthy young adult.
P2860
Q33890580-4F73180A-9776-4EAB-AF65-10890290EE17Q33926114-745F4EA2-2B78-43D9-9A6D-6649DC184DC4Q36739522-94B64B5E-5F62-4F9A-8872-8820AC183A4EQ37025981-32486272-C83C-4C5D-ABBC-99D2C42AADFBQ37026032-B14E62E1-8766-4AF2-BA11-EF93B051A48AQ37095355-2F06B899-F1CE-4465-940E-FD4BDE4B33A0Q37361209-41E9C79C-5C1F-464D-A3F5-4275E56D4C41Q37469835-65916D48-AE91-4750-9C28-EFB8246BFBD0Q38263189-52F14F1D-5BD0-4E84-91A3-C4C4A639256CQ38740209-F6D76561-B9EC-477B-A777-03B4A5B9F175Q40071286-DC41AEA8-5F3B-453E-86D8-4C4730D112B8Q41038941-F3B83308-C66A-4024-B9E0-7703759B523AQ41574173-AD255E91-09BF-4C1A-863E-022D913EA1B8Q42325011-567B4614-7802-470D-95F2-31A5D1D90D53Q42341704-04D8711C-93AB-4241-B0E5-E52799143827Q44774546-64C4FA0B-F072-4FA6-87BD-5FC204C00AECQ47975878-17A922AA-367A-4C0E-B4A6-8614BE96283EQ49338377-B1E880FA-7140-42AC-832F-59A0829AEBFEQ49576201-79118AE4-9B96-4AEB-AF70-3A3DB5B37FE6Q49993294-5B512F7D-AE14-431B-8C6A-1E4D4B0697DCQ50848914-B6DAC7D2-7B7E-42A5-A8D5-53CE1F0379DFQ50871377-F751CC57-5F90-4892-8611-1A12B4F85656Q52677126-776B0C3C-1BE9-476E-AF66-604B7B1E66E1Q55034870-85F0F828-5CDF-43F0-8E05-F40266472228Q55364625-FCD7DF75-0BF4-4E6C-BECA-B84288F27429
P2860
Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Analysis of outcomes in adoles ...... sine kinase inhibitor therapy.
@ast
Analysis of outcomes in adoles ...... sine kinase inhibitor therapy.
@en
type
label
Analysis of outcomes in adoles ...... sine kinase inhibitor therapy.
@ast
Analysis of outcomes in adoles ...... sine kinase inhibitor therapy.
@en
prefLabel
Analysis of outcomes in adoles ...... sine kinase inhibitor therapy.
@ast
Analysis of outcomes in adoles ...... sine kinase inhibitor therapy.
@en
P2860
P50
P1433
P1476
Analysis of outcomes in adoles ...... sine kinase inhibitor therapy.
@en
P2093
Jianqin Shan
Naveen Pemmaraju
P2860
P304
P356
10.3324/HAEMATOL.2011.056721
P50
P577
2012-01-22T00:00:00Z